Orchard Therapeutics is a leading global biotech company focused on transforming the lives of patients with rare diseases through innovative gene therapies. With a fully integrated, commercial-stage approach, Orchard's portfolio includes ex vivo autologous hematopoietic stem cell gene therapy clinical programs targeting Neurometabolic Disorders, alongside early-stage pre-clinical initiatives. Headquartered in London, with a U.S. base in Boston, Orchard is a wholly owned subsidiary of Kyowa Kirin, a Japan-based global specialty pharmaceutical company.